Trial Profile
Low dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Diabetic retinopathy; Postoperative haemorrhage
- Focus Therapeutic Use
- 13 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 18 Mar 2013 Planned End Date 30 Sep 2013 added as reported by University Hospital Medical Information Network - Japan.
- 18 Mar 2013 Planned number of patients changed from 120 to 60 as reported by University Hospital Medical Information Network - Japan.